tert-Butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate | 1367126-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-Butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate
• 英文别名: tert-butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate
• CAS: 1367126-89-3
• 化学式: C₁₄H₁₉Cl₂N₃O₂
• 分子量: 332.2
• InChiKey: BXNNCNQQROWTKE-UHFFFAOYSA-N

物化性质

• 沸点：
  464.6±45.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Alios BioPharma, Inc.

  公开号：US20160244460A1

  公开（公告）日：2016-08-25

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一个或多个抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一个或多个小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• Pyridine Compounds and the Uses Thereof
  申请人：NI Chiyou

  公开号：US20130303526A1

  公开（公告）日：2013-11-14

  The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , A 1 , A 2 , E, G, Z 1 , and Z 2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式（I）的取代吡啶化合物及其药学上可接受的盐、前药和溶剂化物，其中R1a、A1、A2、E、G、Z1和Z2如规范中所述。本发明还涉及使用式（I）的化合物治疗对钠通道阻滞有反应的疾病。本发明的化合物特别适用于治疗疼痛。
• PYRIDINE COMPOUNDS AND THE USES THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150259293A1

  公开（公告）日：2015-09-17

  The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , A 1 , A 2 , E, G, Z 1 , and Z 2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式(I)的取代吡啶化合物及其药学上可接受的盐、前药和溶剂化物，其中R1a、A1、A2、E、G、Z1和Z2如规范中所述。本发明还涉及使用式(I)的化合物来治疗对钠通道阻滞有反应的疾病。本发明的化合物特别适用于治疗疼痛。
• Antiviral compounds
  申请人：Alios BioPharma, Inc.

  公开号：US10358453B2

  公开（公告）日：2019-07-23

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文公开了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物和合成这些化合物的方法。本文还公开了用一种或多种小分子化合物改善和/或治疗副黏液病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• US9056832B2
  申请人：——

  公开号：US9056832B2

  公开（公告）日：2015-06-16